MedDataX Logo

The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise

NCT ID: NCT02418728

Last Updated: 2016-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.

The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.

Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

obesity adipose tissue lipolysis lipolysis microdialysis atrial natriuretic peptide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

persons with obesity

subcutaneous adipose tissue microdialysis under local beta/alpha blockade

Intervention Type OTHER

adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

lean persons

subcutaneous adipose tissue microdialysis under local beta/alpha blockade

Intervention Type OTHER

adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

subcutaneous adipose tissue microdialysis under local beta/alpha blockade

adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obese group: BMI \> 30 kg/m², sedentary (no regular physical activity last 6 months), insulin sensitive or insulin resistant
* Lean controls: BMI \> 18.5 kg/m² and \< 25 kg/m², regular physical activity, insulin sensitive

Exclusion Criteria

* Regular glucose lowering medication or beta blockade medication
* Presence of chronical diseases
* Orthopedic or neurological problems
Minimum Eligible Age

35 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jessa Hospital

OTHER

Sponsor Role collaborator

Maastricht University

OTHER

Sponsor Role collaborator

Hasselt University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dominique Hansen

prof. dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ellen Blaak, prof. dr.

Role: PRINCIPAL_INVESTIGATOR

Maastricht University

Kenneth Verboven, drs

Role: STUDY_CHAIR

Hasselt University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hasselt University

Diepenbeek, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CME2014 /450

Identifier Type: -

Identifier Source: org_study_id